-

InterVenn Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022

SAN FRANCISCO--(BUSINESS WIRE)--InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, the company’s CEO and Co-Founder, is scheduled to present at the J.P. Morgan 40th Annual Healthcare Conference on January 12, 2022, from 3:00 – 3:25 pm EST. Mr. Carrascoso will provide a company overview of InterVenn and its first-of-its-kind glycoproteomics solutions.

Following the company presentation, management will participate in a virtual breakout session. InterVenn management will also participate in one-on-one meetings with investors, analysts, and other interested parties during the conference.

About InterVenn

InterVenn Biosciences has developed a proprietary glycoproteomic biomarker discovery and interrogation platform based on artificial intelligence-empowered mass spectrometry for next-gen precision medicine. The company is working on developing novel predictive tests in a range of indications, including ovarian, pancreatic, liver, prostate, lung, kidney and other cancers, as well as on tests for treatment response prediction and monitoring of treatment efficacy, and disease progression. https://intervenn.com

Contacts

Anthony Petrucci
Bioscribe
anthony@bioscribe.com
512-581-5442

InterVenn Biosciences


Release Summary
InterVenn Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
Release Versions

Contacts

Anthony Petrucci
Bioscribe
anthony@bioscribe.com
512-581-5442

More News From InterVenn Biosciences

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences, the life science company pioneering glycoproteomics co-founded by Nobel Prize winner Carolyn Bertozzi, PhD, Carlito Lebrilla, Ph.D., and Aldo Carrascoso, today announced changes to its senior management team to support its commercialization execution. Erwin Estigarribia, previously InterVenn’s President and Chief Operating Officer, has been appointed as Chief Executive Officer. Laura Beggrow, a commercial-stage business leader...

InterVenn Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences, a life science company pioneering glycoproteomics to improve human health, today announced that senior management will present at the J.P. Morgan 41st annual Healthcare Conference on January 11, 2023 at 8:30 a.m. Pacific. InterVenn’s management team will be available for one-on-one meetings with investors, analysts and other interested parties during the conference. About InterVenn Biosciences InterVenn is a clinical technolog...

InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time. The members of InterVenn’s executive leadership team will be available for one-on-one meetings at the event. A live and archived webcast of...
Back to Newsroom